B Cell-Activating Factor as a New Potential Marker in Inflammatory Bowel Disease

Area of Science:

• Immunology
• Gastroenterology

Background:

• B cell-activating factor (BAFF) is implicated in immune regulation and inflammatory conditions like autoimmunity and B cell malignancies.
• The role of BAFF in inflammatory bowel disease (IBD) has not been previously studied.

Purpose of the Study:

• To investigate the expression and concentration of BAFF in patients with IBD.
• To determine the potential of BAFF as a biomarker for discriminating IBD patients.

Main Methods:

• Serum and fecal BAFF levels were measured using enzyme-linked immunosorbent assay in 78 ulcerative colitis (UC) patients, 37 Crohn's disease (CD) patients, 12 irritable bowel syndrome (IBS) patients, and 44 healthy controls.
• Intestinal BAFF expression was analyzed in biopsy specimens from IBD patients, with localization determined by immunofluorescence.

Main Results:

• Serum BAFF concentrations were significantly higher in CD and UC patients compared to healthy controls.
• Fecal BAFF concentrations were also elevated in IBD patients, demonstrating high sensitivity and specificity for identifying active IBD.
• Intestinal BAFF expression was notably increased in biopsy samples from IBD patients.

Conclusions:

• A novel association between BAFF and IBD suggests BAFF's role in regulating inflammatory processes within these diseases.
• BAFF emerges as a potential diagnostic marker for inflammatory bowel disease.